Lamivudine
20 NDCs across 10 manufacturers|17 Generic,3 Brand
Lamivudine is used to treat acquired immunodeficiency syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Nov 17, 1995, and the first generic was approved Nov 17, 2011. FDA's Orange Book lists 19 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $5 million on Lamivudine across 38,000 claims for 6,137 beneficiaries.
Lamivudine is available as 20 NDCs from 10 manufacturers (17 generic, 3 brand), with NADAC prices from $0.48 to $13.29 per EA — the most expensive product costs about 28× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
20
17G / 3B
Manufacturers
10
competing in market
Price Spread
$0.48 – $13.29
per EA, 17 of 20 NDCs
7d Activity
avg +2.3% WoW · of 20 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
10 manufacturers producing LAMIVUDINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
EPIVIR 300 MG TABLET | $13.2940 per EA | — |
LAMIVUDINE HBV 100 MG TABLET | $9.9043 per EA | -1.32% |
LAMIVUDINE HBV 100 MG TABLET | $8.1597 per EA | — |
EPIVIR 150 MG TABLET | $6.6144 per EA | — |
LAMIVUDINE 300 MG TABLET | $1.3821 per EA | — |
LAMIVUDINE 300 MG TABLET | $1.3719 per EA | +0.57% |
LAMIVUDINE 300 MG TABLET | $1.3719 per EA | +0.57% |
LAMIVUDINE 300 MG TABLET | $1.3719 per EA | +0.57% |
LAMIVUDINE 300 MG TABLET | $1.3014 per EA | — |
LAMIVUDINE 150 MG TABLET | $0.9893 per EA | — |
LAMIVUDINE 150 MG TABLET | $0.5901 per EA | — |
LAMIVUDINE 150 MG TABLET | $0.4887 per EA | +3.98% |
LAMIVUDINE 150 MG TABLET | $0.4887 per EA | +3.98% |
LAMIVUDINE 150 MG TABLET | $0.4887 per EA | +3.98% |
LAMIVUDINE 150 MG TABLET | $0.4887 per EA | +3.98% |
LAMIVUDINE 150 MG TABLET | $0.4887 per EA | +3.98% |
LAMIVUDINE 150 MG TABLET | $0.4797 per EA | — |
EPIVIR 10 MG/ML ORAL SOLN | $0.4452 per ML | — |
LAMIVUDINE 10 MG/ML ORAL SOLN | $0.2176 per ML | — |
LAMIVUDINE 10 MG/ML ORAL SOLN | $0.2176 per ML | — |
Frequently Asked Questions
What is Lamivudine used to treat?
Lamivudine is used to treat acquired immunodeficiency syndrome, per the National Library of Medicine's MED-RT classification.
When did Lamivudine become available as a generic?
FDA approved the first generic Lamivudine (ANDA) on Nov 17, 2011. The Orange Book currently lists 19 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Lamivudine?
In 2024, Medicare Part D spent $5 million on Lamivudine across 38,000 claims for 6,137 beneficiaries.
How many Lamivudine products are on the market?
The Lamivudine drug market contains 20 NDCs from 10 manufacturers — 17 generic and 3 brand products.
What is the price range for Lamivudine?
NADAC reference prices for Lamivudine range from $0.4797 to $13.2940 per EA — the most expensive product costs about 28× the cheapest. 3 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Lamivudine cheaper than brand?
The average generic NADAC for Lamivudine is $1.9577 per EA, versus $9.9542 for brand-labeled products — brand versions average about 5.1× the generic price.
Which manufacturers make Lamivudine?
10 manufacturers list Lamivudine in NADAC. Ranked by number of NDCs, the largest are ViiV Healthcare Company (3), Apotex Corp. (3), Camber Pharmaceuticals Inc. (3), Aurobindo Pharma Limited (3), Strides Pharma Inc. (2).
How has the price of Lamivudine changed recently?
Over the past 7 days, 16 Lamivudine NDCs rose and 2 fell, with a market-wide average change of +2.3%.